Current and Future Perspectives on Adipo‐Oncology: Roles of Adipocytes in Local and Systemic Tumor Regulation Authors: Shinya Sato Published: 2026 ABSTRACT ABSTRACTAdipose tissue has traditionally been regarded as an energy‐storage organ; however, accumulating evidence indicates that adipocytes actively regulate cancer biology through local and systemic mechanisms. These findings have contributed to the emergence of adipo‐oncology, an interdisciplinary field focused on interactions between adipose tissue and cancer. This review summarizes current evidence on the local and systemic roles of adipocytes in tumor progression and discusses how tissue heterogeneity and plasticity may influence these processes. Locally, adipocytes adjacent to tumors may be reprogrammed into cancer‐associated adipocytes that promote tumor progression through enhanced lipolysis and inflammatory signaling, paracrine adipokine and cytokine secretion, local lipid transfer, and modulation of stromal and immune cell populations within the tumor microenvironment. Systematically, adipocytes may influence metabolic remodeling, epithelial–mesenchymal transition, invasion, metastasis, therapeutic resistance, and establishment of tumor‐promoting niches. Additionally, adipocyte plasticity and epigenetic reprogramming have emerged as important determinants of adipocyte function during cancer progression. Collectively, these findings support a model in which adipocytes function as central regulators of cancer biology at local and systemic levels. A deeper understanding of the molecular basis of adipo‐oncology may provide new insights into tumor progression and facilitate the development of metabolic, immunological, and epigenetic therapeutic strategies targeting adipose tissue.Keywords: adipokines, adipose tissue, cancer‐associated adipocyte, extracellular vesicles, lipid metabolism, obesity, tumor microenvironment Abbreviations acute myeloid leukemia AMP‐activated protein kinase bone marrow adipose tissue cancer‐associated fibroblast C–C motif chemokine ligand 2 C–C motif chemokine receptor 2 Carnitine palmitoyltransferase 1A C–X–C motif chemokine ligand 8 epithelial–mesenchymal transition extracellular vesicle fatty acid‐binding protein 4 fibroblast activation protein free fatty acid hypoxia inducible factor 1‐alpha interleukin myeloid‐derived suppressor cell matrix metalloproteinases proliferating cell nuclear antigen programmed death‐ligand 1 procollagen‐lysine,2‐oxoglutarate 5‐dioxygenase 2 subcutaneous adipose tissue serum amyloid A1 transforming growth factor beta tumor microenvironment visceral adipose tissue vascular endothelial growth factor vascular endothelial growth factor alpha–smooth muscle actin Introduction In recent years, adipose tissue has been recognized not merely as an energy‐storage tissue but also as a dynamic endocrine organ involved in systemic homeostasis. Adipose tissue is distributed across multiple anatomical depots, including subcutaneous, visceral, bone marrow, and mammary gland adipose tissues, and can establish close spatial and functional interactions with various cancer types. Accordingly, adipose tissue–cancer interactions are increasingly recognized as a common feature across diverse malignancies rather than a phenomenon restricted to specific organs. With the increasing prevalence of obesity, accumulating evidence from basic and clinical research indicates that adipose tissue‐derived signaling contributes to cancer development and progression [1, 2, 3]. However, an integrated framework that encompasses both local tumor–adipose tissue interactions and systemic metabolic effects remains limited. Our group recently proposed “adipo‐oncology” as a conceptual framework for understanding cancer–adipose tissue crosstalk at local and systemic levels [4]. This emerging field may provide new insights into adipose tissue‐mediated tumor regulation and help identify therapeutic opportunities through the integration of basic, clinical, and translational research. Cancer–adipose tissue interactions can be broadly categorized as local or systemic. Locally, adipocytes within the tumor microenvironment (TME), together with stromal components such as immune cells, blood vessels, lymphatic vessels, nerves, and fibroblasts, contribute to tumor progression through direct and indirect interactions with cancer cells (Figure 1). Local adipocyte–cancer crosstalk has been implicated in cancer cell proliferation, invasion, metastasis, and therapeutic resistance through fatty acid transfer, extracellular matrix remodeling, cytokine production, and adipocyte reprogramming [5, 6, 7]. Schematic overview of metastatic tumor microenvironment. Stromal cells in the metastatic microenvironment comprise various cell types, including fibroblasts, immune cells, endothelial cells, nerve cells, and adipocytes which interact with tumor cells. Systemically, adipose tissue‐derived secretory factors, such as adipokines, cytokines, lipid metabolites, and exosomes, influence distant organs through the circulation and may indirectly modulate cancer development and progression by altering the TME, host immunity, and systemic metabolism [1, 2, 3]. This review focuses on the multifaceted interactions between adipose tissue and cancer, highlighting recent advances in local adipocyte–cancer cell crosstalk and systemic tumor‐regulatory mechanisms mediated by adipose tissue‐derived factors. We also discuss heterogeneity in tumor cell dependence on adipocyte interactions, adipocyte functional diversity, and the implications of cancer–adipocyte crosstalk for tumor biology and therapeutic strategies. Local Effects of Adipocytes in the Tumor Microenvironment Cancer‐Associated Adipocyte Formation and Tumor Microenvironment Remodeling In the TME, adipocytes can shift from their normal endocrine and supportive functions and be reprogrammed by tumor‐derived factors into cancer‐associated adipocytes (CAAs) [8, 9, 10]. CAAs are characterized by increased free fatty acid (FFA) secretion, elevated inflammatory cytokine production, and ECM remodeling, which contribute to the formation of a tumor‐promoting niche [11]. Increased expression of interleukin (IL)−6 and matrix metalloproteinases (MMPs) within the TME has been reported to induce fibroblast‐like activity and the partial acquisition of CAF‐like functions [8]. During this process, adipocytes increase the production of inflammatory molecules, such as IL‐6, IL‐1β, and MMP11, which contribute to increased tumor cell invasiveness and metastasis. The acquisition of CAF‐like features by adipocytes involves activation of the Wnt/β‐catenin pathway by tumor‐secreted Wnt3a, and these reprogrammed adipocytes further enhance tumor cell invasiveness [12]. CAAs also increase serum amyloid A‐1 (SAA1) expression in pancreatic cancer cells, thereby promoting invasiveness, treatment resistance, and epithelial–mesenchymal transition (EMT) [13]. In our previous study, we observed coexpression of perilipin and α‐smooth muscle actin in adipocytes near the leading edge of cancer invasion in bone metastases, suggesting fibroblast‐like transformation of adipocytes [14]. Together, these findings suggest that adipocytes in the TME can be reprogrammed by adjacent tumor cells and acquire functions that support tumor progression. Paracrine Signaling From Adipocytes to Cancer Cells Through Adipokines and Cytokines Within the TME, adipocytes release various secretory factors. Adipocyte‐derived adipokines and cytokines form local concentration gradients and directly influence cancer cell survival and proliferation. Adipocyte‐derived leptin activates the JAK2–STAT3 pathway through the leptin receptor (LEPR) on cancer cells within the local TME [15]. This signaling promotes cancer cell proliferation, exerts anti‐apoptotic effects, and stimulates angiogenesis within the microenvironment [15]. Leptin also activates the PI3K/AKT pathway in parallel with the JAK2–STAT3 pathway via LEPR signaling in the TME, thereby promoting proliferation, invasion, and metastasis in breast cancer cells by increasing procollagen‐lysine,2‐oxoglutarate 5‐dioxygenase 2 (PLOD2) expression [16]. Local leptin further promotes IL‐18 secretion by tumor cells through PI3K/AKT pathway activation, thereby enhancing tumor cell invasion and metastasis [17]. IL‐6 secreted by adipocytes in the TME activates STAT3 through the gp130/IL‐6R complex, inducing PLOD2 expression in cancer cells, strengthening ECM crosslinking, and enhancing invasiveness [18]. IL‐8 produced by CAAs binds receptors on ovarian cancer cells and promotes homing to adipose tissue [19]. Monocyte chemoattractant protein‐1 (MCP‐1) produced by omental adipocytes binds to the C‐C motif chemokine receptor 2 (CCR2) receptor on ovarian cancer cells and activates the PI3K/AKT/mTOR pathway and its downstream effectors, hypoxia‐inducible factor 1‐alpha (HIF‐1α) and vascular endothelial growth factor (VEGF)‐A, thereby promoting cell migration and omental dissemination [20]. Adipocyte‐derived TNF‐α in the TME activates the IKK–NF‐κB pathway in cancer cells, inducing the expression of EMT‐related transcription factors, such as SNAIL and TWIST, and enhancing tumor plasticity [19]. These findings indicate that locally produced adipocyte‐derived adipokines and chemokines in the TME may substantially influence local tumor behavior. Adipocyte‐Derived Lipid Transfer and Its Effects on Tumor Metabolism and Aggressiveness in the Tumor Microenvironment In the TME, adipocytes function as a lipid source for cancer cell survival and proliferation and form a metabolic network with cancer cells. Adipocytes enhance lipolysis and support tumor metabolism by supplying FFAs to the TME [7]. Tumor cells co‐cultured with adipocytes show increased expression of fatty acid‐binding protein 4 (FABP4), a fatty acid transporter, along with increased cell proliferation, as indicated by proliferative cell nuclear antigen (PCNA) expression [21]. In leukemia, acute myeloid leukemia (AML) blasts induce phosphorylation of hormone‐sensitive lipase in adipocytes, thereby activating lipolysis and promoting FFA transfer from adipocytes to AML blasts. Co‐culture experiments involving AML blasts and adipocytes have also shown increased FABP4 expression in both cell types [22]. CD36 in AML cells transports very‐long‐chain and long‐chain fatty acids [23]. The CD36 inhibitor SMS121 reduced fatty acid uptake by AML cells co‐cultured with adipocytes, resulting in decreased AML cell viability [23]. Carnitine palmitoyltransferase 1 A (CPT1A) is a key regulator of fatty acid oxidation and energy production from fatty acids. Co‐culture with adipocytes increased CPT1A expression in colorectal cancer cells, whereas CPT1A silencing suppressed cell proliferation and tumor organoid formation [24]. Adipocyte‐mediated fatty acid metabolism also affects cancer stem cell function. CPT1A suppression, together with fatty acid metabolism inhibition, reduces the expression of Wnt/β‐catenin downstream target genes associated with cancer stem cell function in colorectal cancer cells [24, 25]. Overall, adipocytes within the TME support tumor cell survival and proliferation by supplying FFAs and may influence tumor growth and cancer stem cell function. Effects of Local Adipocytes on Stromal and Immune Components in the TME In the TME, adipocytes exert broad effects not only on tumor cells but also on surrounding stromal, immune, and vascular cells, thereby indirectly regulating tumor progression. Among stromal cells, cancer‐associated fibroblasts (CAFs) are activated by adipocyte‐derived IL‐6 and transforming growth factor beta (TGF‐β) [19], contributing to tumor‐supportive structure formation through ECM production. Adipocytes derived from patients with obesity and breast cancer also exhibit a myoCAF‐associated phenotype and express myofibroblast‐related genes, including fibroblast activation protein alpha (FAP) and α‐smooth muscle actin [26]. Among myeloid cells, inflammatory adipocytes surrounding breast cancer cells regulate tumor‐associated macrophage (TAM) accumulation around tumors [27]. Adipocytes within the TME also promote M2 macrophage recruitment and polarization through C–C motif chemokine ligand 2 (CCL2) secretion [28, 29]. MyoCAF‐associated adipocytes derived from patients with obesity and breast cancer similarly promote M2 macrophage recruitment and polarization [26]. Adipocytes further contribute to an immunosuppressive microenvironment by promoting myeloid‐derived suppressor cell (MDSC) recruitment and differentiation through CCL2 secretion [28, 29]. Regarding adaptive immune cells, adipocytes modulate the function of CD8‐positive T lymphocytes, which play a central role in antitumor immunity. Specifically, 12,13‐dihydroxy‐9Z‐octadecenoic acid, secreted by pancreatic CAAs, suppresses CD8‐positive T‐lymphocyte function by promoting CXCL2 secretion from tumor‐associated neutrophils [30]. Tumor‐associated adipocytes also induce functional exhaustion of CD8‐positive T lymphocytes by impairing mitochondrial function through lipid peroxidation associated with FGF21‐promoted adipocyte lipolysis [31]. In our study, we observed a reduced density of CD8‐positive T lymphocytes in the adipocyte‐rich leading edge (Adipo‐BM) of bone metastases compared with the hematopoietic cell‐rich leading edge (Hemato‐BM). Several factors may potentially contribute to this finding, including adipokines and other adipocyte‐derived factors, the extent of tumor infiltration, and the complex invasive morphology observed in Adipo‐BM. However, these possibilities remain speculative because functional analyzes were not performed in the original study. Further investigations, including in vitro and in vivo experiments combined with spatial analyzes, will be required to directly elucidate the underlying mechanisms and biological significance of these observations [14]. Taken together, local adipocytes within the TME influence the function and polarization of multiple stromal and immune cell populations, including CAFs, macrophages, MDSCs, and CD8‐positive T lymphocytes, thereby potentially shifting the TME toward a tumor‐promoting state. Systemic Regulation of Cancer by Adipocyte‐Derived Factors Adipokine‐Mediated Systemic Regulation of Cancer Adipokines are cytokine‐like mediators secreted primarily by adipocytes and play key roles in the systemic regulation of cancer by adipose tissue. Leptin is a representative adipokine with circulating levels that are elevated in obesity [32, 33, 34]. Leptin binds to its receptor, LEPR [35], and promotes tumor cell proliferation, angiogenesis, and EMT through activation of the JAK/STAT3, PI3K/AKT, and MAPK pathways [15]. In addition to LEPR‐mediated signaling, leptin promotes activation of the Notch and IL‐1 signaling pathways. Crosstalk among these pathways enhances proliferation, invasiveness, and drug resistance in endometrial cancer cells, whereas administration of a leptin‐signaling antagonist restores drug sensitivity in endometrial cancer cell lines [36]. Leptin signaling has also been implicated in the maintenance of breast cancer stem cell properties [37]. Activation of leptin signaling also attenuates the antitumor efficacy of anti‐CTLA4 immunotherapy in renal cell carcinoma models [38]. Adiponectin is an adipocyte‐specific adipokine and, together with leptin, is among the most extensively studied adipokines in cancer biology [32, 39, 40, 41]. In contrast to leptin, adiponectin is generally considered to exert tumor‐suppressive effects [42, 43, 44, 45]. Exposure of breast cancer cell lines to adiponectin induces apoptosis and cell‐cycle arrest through AMP‐activated protein kinase (AMPK) signaling activation and p42/44 MAPK signaling inhibition [46]. In renal cell carcinoma, knockdown of the adiponectin receptor AdipoR1 promotes tumor cell proliferation, invasion, and intratumoral angiogenesis in vivo through suppression of AMPK signaling [47]. Activation of the AdipoR1–AMPK pathway in hormone receptor‐positive and triple‐negative breast cancer cell lines also increases the expression of apoptosis‐ and ferroptosis‐related genes. In hormone receptor‐positive breast cancer cells, this pathway also reduces estrogen receptor expression [48]. Other adipokines, including resistin and visfatin, have been reported to promote tumor progression by stimulating cell proliferation and inducing EMT. However, many aspects of their biological functions and underlying molecular mechanisms remain incompletely understood and require further investigation [4, 49, 50]. Taken together, adipocyte‐derived adipokines, particularly leptin and adiponectin, may systemically regulate the behavior of multiple cancers and represent important mediators linking adipose tissue to cancer progression. Adipocyte‐Derived Inflammatory Cytokines and Systemic Tumor Immunity Inflammatory cytokines are released from adipose tissue during obesity and chronic inflammation and can thereby influence systemic tumor immunity. Early studies demonstrated increased circulating levels of inflammatory cytokines and acute‐phase proteins, including IL‐6, IL‐8, C‐reactive protein (CRP), serum amyloid A, and MCP‐1, in patients with obesity and mouse models of obesity. These findings suggest that adipose tissue‐derived inflammatory mediators may play important roles in regulating tumor immunity [51, 52, 53, 54, 55]. Among these factors, adipocyte‐derived IL‐6 directly affects both cancer and immune cells. In cancer cells, IL‐6 activates the JAK/STAT3 signaling pathway, leading to increased PD‐L1 expression and reduced NKG2D expression and thereby diminishing the cytotoxic activity of natural killer cells [56]. Adipocyte‐derived IL‐6 also promotes macrophage infiltration into tumors and induces M2 macrophage polarization by activating JAK/STAT3 signaling [57]. MCP‐1, also known as CCL2, is secreted by adipocytes and binds to C–C motif chemokine receptor 2 (CCR2) expressed on macrophages, thereby enhancing macrophage migratory capacity and promoting macrophage infiltration into tumors [58]. Pharmacological inhibition of adipocyte‐derived CCL2 secretion by hesperidin suppresses M2 macrophage infiltration while promoting CD8‐positive T‐lymphocyte infiltration in mouse tumor models [59]. Adipocyte‐derived C–X–C motif chemokine ligand 8 (CXCL8) also contributes to immune suppression by increasing programmed death‐ligand 1 (PD‐L1) expression in cancer cells and reducing the tumor‐killing activity of CD8‐positive T lymphocytes [60]. Taken together, systemic secretion of adipose tissue‐derived cytokines and chemokines can alter the function, localization, and polarization of multiple immune cell populations, thereby contributing to tumor immunity regulation. Systemic Regulation of Tumor Metabolism and Malignant Phenotypes Through Adipocyte‐Derived Lipid Uptake Adipocytes secrete FFAs, which enter the systemic circulation and can be taken up by tumor cells. After uptake, FFAs activate lipid metabolic pathways and contribute not only to energy production but also to tumor proliferation, metastasis, and therapeutic resistance [61]. Experimental studies in mice have shown that aging alters both the quantity and composition of FFAs released from adipocytes. These changes may contribute to ovarian cancer progression by reducing the abundance of specific FFAs with tumor‐suppressive properties [62]. Adipocyte‐derived FFAs also activate STAT3 and PPARα signaling pathways, thereby promoting glycolysis and metastatic potential in triple‐negative breast cancer [63]. The role of fatty acid uptake in tumor progression is further supported by studies targeting lipid transport mechanisms. Inhibition of FABP4, a key mediator of fatty acid transport and uptake, suppresses ovarian cancer metastasis [19, 64]. Similarly, pharmacological inhibition of CD36, another major fatty acid transporter expressed on tumor cells, reduces tumor cell proliferation [65]. Taken together, systemically circulating adipocyte‐derived lipids can alter tumor metabolism and contribute to the acquisition of malignant phenotypes, including enhanced proliferation, metastasis, and treatment resistance. Functional Regulation of Tumors by Systemically Circulating Adipocyte‐Derived Extracellular Vesicles Adipose tissue releases large quantities of extracellular vesicles (EVs) into the systemic circulation. These EVs contain various bioactive molecules, such as miRNAs, lipids, metabolic enzymes, and inflammatory mediators, and can modulate the TME at distant sites [66, 67]. Adipocyte‐derived EVs may enhance tumor progression through multiple mechanisms. In melanoma, adipocyte‐derived EVs supply fatty acid oxidation‐related enzymes together with fatty acids, thereby providing metabolic substrates that enhance tumor cell motility [68]. In breast cancer, adipocyte‐derived EVs promote EMT through the delivery of thrombospondin family protein 5 [69]. EVs derived from mouse adipocytes also increase the motility and invasiveness of breast cancer cells by upregulating MMP2 and MMP9 expression. These EVs also induce the expression of stemness‐associated markers, including CD44 and OCT4, thereby contributing to the acquisition of cancer stem cell‐like properties [70]. Obesity‐associated changes in adipocyte‐derived EVs may further enhance tumor aggressiveness. EVs isolated from hypertrophic adipocytes of obese mice exhibit increased lipid content and promote lipid transfer to breast cancer cells in co‐culture systems [71]. Furthermore, miR‐660‐5p, an miRNA enriched in adipocyte‐derived EVs, has been identified as a poor prognostic factor after radiotherapy in patients with esophageal squamous cell carcinoma [72]. Taken together, adipocyte‐derived EVs may contribute to tumor malignancy by systemically transferring lipids, proteins, miRNAs, and other bioactive molecules, thereby promoting tumor cell motility, invasiveness, stemness, and metabolic adaptation. These findings indicate that adipose tissue regulates metabolic signaling and immune responses through diverse circulating humoral factors, thereby influencing tumor initiation and progression. In particular, obesity‐associated qualitative changes in adipocytes may promote carcinogenesis, metastasis, and therapeutic resistance. Together, these findings highlight the multifaceted roles of adipocytes in tumor regulation; the major local and systemic mechanisms are summarized in Table 1. Table 1Local and systemic mechanisms of adipocyte‐mediated tumor regulation.Adipocyte‐mediated mechanismMajor mediatorsPrincipal targetsBiological consequencesLocal regulation (TME)Cancer‐associated adipocyte (CAA) formationLipolysis‐related factors, inflammatory mediatorsAdjacent tumor cellsMetabolic reprogramming, EMT, invasion, metastasis, therapeutic resistanceParacrine adipokine/cytokine signalingLeptin, adiponectin, IL‐6, TGF‐β, CCL2, CXCL8, etc.Tumor cells and neighboring stromal cellsTumor proliferation, EMT, angiogenesis, immune evasionLocal lipid transferFFAs, FABP4‐mediated transport, CD36‐mediated uptakeTumor cellsEnhanced fatty acid oxidation, metabolic adaptation, metastatic potentialRegulation of stromal and immune cellsAdipokines, cytokines, lipid mediatorsCAFs, TAMs, MDSCs, CD8 + T cells, endothelial cells, ECMTME remodeling, immunosuppression, angiogenesis, tumor‐supportive niche formationSystemic regulationAdipokine‐mediated regulationLeptin, adiponectin, resistin, visfatinDistant tumor cellsRegulation of proliferation, stemness, angiogenesis, therapy responseInflammatory cytokine‐mediated regulationIL‐6, MCP‐1/CCL2, CXCL8, CRP, SAAImmune cells and tumor cellsSystemic inflammation, macrophage recruitment, immune suppressionLipid‐mediated regulationCirculating FFAs, lipid metabolitesTumor cells at distant sitesMetabolic rewiring, tumor growth, metastasis, therapy resistanceExtracellular vesicle (EV)‐mediated regulationmiRNAs, lipids, metabolic enzymes, proteinsDistant tumor cells and metastatic nichesEMT, stemness, invasiveness, metabolic adaptation, metastatic progression Local and systemic mechanisms of adipocyte‐mediated tumor regulation. Emerging Topics in Adipocyte Heterogeneity Adipose tissue exhibits marked functional differences according to its anatomical location. Subcutaneous adipose tissue (SAT), visceral adipose tissue (VAT), and bone marrow adipose tissue (BMAT) have distinct developmental origins, progenitor cell populations, metabolic characteristics, and secretory profiles [73, 74, 75]. The composition of immune cells and adipocyte progenitor populations also varies substantially across adipose depots, leading to considerable cellular heterogeneity. Compared with SAT, VAT exhibits greater production of inflammatory cytokines and FFAs and has been associated with stronger tumor‐promoting effects [76, 77]. BMAT is a specialized adipose tissue distinct from both white and brown adipose tissue and plays a unique role in the bone microenvironment. Bone marrow adipocytes have been reported to promote bone metastasis and progression of hematological malignancies by providing fatty acids, CXCL family chemokines, IL‐6, and adipokines that support tumor growth and survival within the bone marrow niche [78]. Bone marrow adipocytes also share common progenitors with osteoblasts, increase in abundance with aging and obesity, and function as metabolic support cells during the establishment of bone metastases [79]. Taken together, these findings suggest that the anatomical location of adipose tissue may influence both local TME formation and organ‐specific patterns of tumor progression and metastasis. Adipocytes themselves also exhibit considerable functional heterogeneity. White adipocytes primarily function in energy storage and inflammatory adipokine secretion, whereas brown adipocytes are specialized for UCP1‐dependent thermogenesis and are characterized by high mitochondrial activity. Beige adipocytes represent a plastic adipocyte population that can emerge from white adipocytes and acquire brown adipocyte‐like characteristics in response to metabolic stimuli. These adipocyte subtypes differ substantially in lipid mobilization, oxidative metabolism, cytokine secretion, and extracellular vesicle content, potentially resulting in distinct effects on tumor development and progression [76, 78, 80]. In addition to the heterogeneity of adipose tissues and adipocyte populations, tumor heterogeneity should also be considered. Cancer cells differ substantially according to tissue of origin, histological subtype, and genetic background, all of which may influence adipocyte–tumor interactions. Nevertheless, direct comparisons of adipocyte‐associated factors among different cancer types have not yet been systematically performed, and many questions regarding tumor‐specific differences remain unresolved. Further studies are needed to determine how adipocyte‐mediated regulatory mechanisms vary across distinct tumor types and biological contexts and to identify both shared and tumor‐specific pathways. Discussion This review outlines how adipocytes regulate tumor progression through local and systemic mechanisms. However, adipose tissue as a single homogeneous entity has important limitations. As discussed in Section 3, the localization and cellular heterogeneity of adipose tissue have emerged as key determinants of adipocyte‐mediated tumor control in recent years. The marked plasticity of adipocytes is particularly important. Adipocytes adjacent to tumors can be reprogrammed by cancer cell‐derived signals into CAAs, which exhibit enhanced lipolysis, increased inflammatory cytokine production, and ECM remodeling. Peritumoral adipocytes have been reported to undergo dedifferentiation and acquire an inflammatory phenotype that promotes tumor invasion [19]. Recent studies have further demonstrated that epigenetic regulation plays a central role in controlling adipocyte identity and function. In addition to transcriptional networks centered on PPARγ, C/EBPα, and PRDM16, histone modifications, DNA methylation, and chromatin remodeling contribute to adipocyte differentiation and functional maintenance [76, 78]. The epigenetic state of adipocytes is highly dynamic and can be reshaped by local and systemic environmental cues during tumor progression. Obesity, aging, and chronic inflammation may alter the adipocyte epigenome, thereby promoting a shift toward inflammatory and tumor‐supportive adipocyte phenotypes. Consistent with this concept, BMAT increases with age and has been associated with the establishment of a niche that facilitates bone metastasis [79, 81], suggesting that changes in adipocyte state may contribute to metastatic niche formation. These findings highlight adipocytes as potential therapeutic targets. Although conventional anticancer therapies have primarily focused on directly eliminating tumor cells, emerging strategies may instead target the tumor‐supportive niche by modulating the metabolic, differentiation, inflammatory, and epigenetic states of adipocytes. Such approaches may be particularly relevant in metastatic disease because adipose‐rich tissues, such as the omentum and bone marrow, are major metastatic sites. Therefore, therapeutic interventions targeting adipocyte–tumor interactions may have clinical significance [77, 78, 79]. Conclusion Adipocytes locally promote metabolic remodeling of cancer cells, epithelial–mesenchymal transition (EMT), invasion, metastasis, and drug resistance through cancer‐associated adipocyte (CAA) formation, adipokine and cytokine paracrine signaling, lipid supply, and regulation of surrounding stromal cells. In parallel, they remodel the entire tumor microenvironment (TME), including cancer‐associated fibroblasts (CAFs), macrophages, T cells, vascular endothelial cells, and the extracellular matrix (ECM). Systemically, adipose tissue regulates tumors at distant sites through adipokines, inflammatory cytokines, lipids, and extracellular vesicles (EVs) released into the circulation. These regulatory mechanisms are likely to become even more complex among individual patients owing to depot‐specific characteristics of adipose tissue, including subcutaneous adipose tissue (SAT), visceral adipose tissue (VAT), and bone marrow adipose tissue (BMAT), functional diversity among white, beige, and brown adipocytes, and the plasticity of adipocytes in response to changes in the TME. Adipose tissue is being redefined not merely as a tissue surrounding tumors, but as a central organ that regulates cancer biology at both local and systemic levels. Deepening our understanding of adipocyte–tumor interactions will not only provide new insights into the mechanisms underlying tumor progression but also establish an important foundation for the development of novel therapeutic strategies. Furthermore, translating the molecular mechanisms of adipo‐oncology into clinically applicable therapies will require a more comprehensive understanding of site‐specific adipocyte heterogeneity through single‐cell and spatial transcriptomics, as well as a deeper characterization of systemic adipocyte‐derived signaling networks by analyzing circulating secreted factors across different cancer types and disease stages. Ultimately, metabolic, immunological, and epigenetic interventions targeting adipose tissue may emerge as next‐generation therapeutic strategies for a broad range of patients with cancer. Author Contributions Shinya Sato contributed to the conception of this study and wrote the article and figures. Conflicts of Interest The authors declare no conflicts of interest. Acknowledgments The author has been announced as the winner of The Japanese Society of Pathology; Pathology Research Award in 2024. We would like to thank Yohei Miyagi, Naohiko Koshikawa, Takuro Nakamura, Yutaka Kondo, Toshinari Yamashita, Yukihide Ota, Hirotaka Nagasaka, Atsuto Suzuki, Mitsuyuki Koizumi, Takashi Yamanaka, Haruhide Udagawa, Yoshiyasu Nakamura, Yukako Komori, Mitsuyo Yoshihara, Mutsumi Ishida, and Kumiko Ohrui for supporting this study. Figures were created using BioRender.com. Shinya Sato received the Japan Society for the Promotion of Science (JSPS) Grants‐in‐Aid for Scientific Research (KAKENHI; grant No. 23K08708, 26K09939). Shinya Sato also received research funding from Nikon Corporation and Takeda Pharmaceutical Company. Data Availability Statement Data sharing not applicable to this article as no datasets were generated or analyzed during the current study. References Associated Data Data Availability Statement Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.